Technology collaboration OFFER
Abstract
An Austrian university offers the first treatment option for Friedreich´s Ataxia (FRDA), an inherited neurodegenerative disease. It causally targets FRDA
using Erythropoietin (EPO) to increase the level of Frataxin, decreased levels of which are reportedly responsible for the development of FRDA. So far
no other effective treatment is available which is at an advanced development stage. Industrial partners for further developing & commercialising
EPO for the treatment of FRDA are sought.
Date de creation: 23 July 2010
Tuesday, July 27, 2010
Subscribe to:
Posts (Atom)
